PIK3CA and head and neck squamous cell carcinoma: Buparlisib, an oral small molecule and pan-PI3K inhibitor, is currently in an advanced stage of clinical testing and is being investigated in a phase 3 trial in SCCHN patients with recurrent/metastatic squamous tumors following progression to a platinum-containing regimen, as well as to check-point inhibitor-based immunotherapy [52].